<DOC>
	<DOCNO>NCT03048942</DOCNO>
	<brief_summary>90 patient HER2 negative breast cancer randomise receive 18 week chemotherapy treatment , either 6 cycle 3 weekly Cabazitaxel 6 cycle weekly Paclitaxel determine difference progression free survival 2 group . If result stage suggest potential benefit trial develop accrue 70 patient .</brief_summary>
	<brief_title>Pilot Study Cabazitaxel Paclitaxel HER2 Negative Breast Cancer</brief_title>
	<detailed_description>This prospective multicentre , randomise , open label , study compare efficacy safety six 3-weekly cycle cabazitaxel versus 18 x weekly paclitaxel give first line chemotherapy treatment patient HER2-normal metastatic breast cancer . Randomisation conduct 1:1 ratio .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written inform consent Metastatic breast cancer fit receive cytotoxic chemotherapy metastatic disease Measurable disease per RECIST 1.1 HER2 negative define ICH 0+ , 1+ 2+ FISH/SISH/CISH ( ration &lt; 2.0 ) case IHC 2+ ECOG performance status 0 1 ER+ve ERve Female age ≥18 year Anticipated life expectancy &gt; 6 month Haemoglobin &gt; 10.0g/DL Absolute neutrophil count &gt; 1.5 x 10^9/L Platelet count &gt; 100 x 10^9/L ALT/SGPT &lt; 1.5 X ULN Serum creatinine &lt; 1.5 x ULN Negative pregnancy test woman child bear potential Grade ≥2 oral mucositis peripheral sensory neuropathy History malignancy History severe hypersensitivity ≥grade 3 polysorbate 80 contain drug taxanes Clinically significant cardiovascular disease Any acute chronic medical condition Acute infection require systemic antibiotic antifungal medication Sex hormones Administration live vaccine within 8 week Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4/5 Participation another clinical trial investigational drug within 30 day randomisation Pregnant breast feed woman Contraindications use corticosteroid treatment HER2 Positive breast cancer Previous Paclitaxel chemotherapy adjuvant set Previous cytotoxic chemotherapy metastatic disease Palliative radiotherapy metastatic disease within 4 week randomisation Symptomatic brain metastasis confirm CT/MRI brain History malignancy Grade 2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>